Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Americas
The US Food and Drug Administration (FDA) has approved the first generic versions of antidepressant drug Cymbalta (duloxetine hydrochloride), after Eli Lilly’s primary patent covering the product expired on December 11.   16 December 2013
Americas
Canadian law firm Davis LLP has strengthened its life sciences department with the addition of Sara Zborovski as partner.   13 December 2013
Asia-Pacific
The High Court in Australia has said for the first time that a method of medical treatment for the human body can be a patentable invention.   12 December 2013
Americas
Six US congressman have implored President Barack Obama to ensure that the Trans Pacific Partnership does not include measures that undermine access to affordable healthcare.   11 December 2013
Biotechnology
Europe’s main life sciences laboratory has made a database containing details of around 15 million patented chemical structures available to the public for the first time.   11 December 2013
Americas
The rapidly-evolving field of life sciences presents a variety of unique IP challenges, which were debated at this year's PanEuropean IP Summit in Paris.   10 December 2013
Big Pharma
At the PanEuropean IP Summit on Tuesday, a panel discussion revealed different attitudes toward the introduction of the Unitary Patent and Unified Patent Court.   10 December 2013
Americas
Speaking at Wednesday's C5 Congress on Biotech and Pharma Patenting in London, Michael McGraw, a partner from Fitzpatrick, Cella, Harper and Scinto in New York, considered the line that separates natural and man-made products.   5 December 2013
Big Pharma
At the 3rd C5 Forum on Biosimilars in London on Wednesday, a panel of lawyers and regulatory experts discussed the lie of the land for biosimilars.   5 December 2013
Biotechnology
Aliki Nichogiannopoulou, director of biotechnology at the European Patent Office, outlined best practices for patenting antibodies at the office while speaking at the 25th C5 Congress on Biotech and Pharma Patenting in London on Wednesday.   4 December 2013